Skip to content

Colon Cancer Prognosis After Radical Surgery

Prognosis of Colon Cancer. Clinical and Pathological-anatomical Factors Concerned With Radical Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00963352
Enrollment
300
Registered
2009-08-21
Start date
2007-01-31
Completion date
2010-12-31
Last updated
2010-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

Colon cancer, Open surgery resection, Laparoscopic surgery resection, Morbidity, Mortality, Metastases, Oncology, Freedom of malignant disease recurrence, Safety of intervention open and laparoscopic, Examination of adverse markers, Development of metastases in lungs and other organs

Brief summary

1. Radical surgery. It is supposed to improve prognosis of colon cancer. A surrogate measure of achievement of radical surgery is the number of lymph nodes removed with the specimen. 2. Markers. There may be variables that may make patient assessment more sound. The project is including investigation of such markers (genes, old age, comorbidity, and others). 3. Laparoscopic resections. This is being used more and more in cancer surgery but the feasibility of this approach remains to be proven compared with conventional open surgery. The project compares these according to 1) and 2). 4. Morbidity and mortality must be surveilled to keep at a minimum. Many patients have comorbidity and are old to make this factor extra important, including perioperative care. 5. Proper treatment of colon metastases may prolong life. Treatment of lung-metastases will be studied in particular.

Detailed description

1. Radical surgery. A detailed description of procedures for each location of tumor in the large intestine is used. By following a given procedure for each location in the large intestine, the number of lymph nodes can be analyzed for each location to find out if this differs and if prognosis is affected by lymph node numbers according to tumor site. 2. Markers. Different variables are examined for use in clinical judgment to make treatment better as well as genetic experimental analyses for comparison with clinical outcome to better understanding of clinical behavior. 3. Laparoscopic resections. The technical challenge of laparoscopic approach has been compared with conventional surgery without any difference being observed in trials. However, it should be compared with radical open surgery to compare best achievements by using number of lymph nodes as well as outcome measures in the short and long term (mortality). 4. Comorbidity, old age itself, type of surgery and perioperative care according to the so called fast track surgery may all play a part in reducing perioperative morbidity and mortality. A maximum 3% mortality should be aimed for. 5. Colon cancer usually metastasize to the liver and lungs. Surgical treatment of liver metastases has been extensively studied and the prognosis has improved. Lung metastases has not been given similar attention but the prognosis of those operated may be good and equal that after liver surgery. The need for pulmonary resection and factors associated with metastases and lung metastases in particular will be studied.

Interventions

None listed

Sponsors

Haraldsplass Deaconess Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Malignant tumor (adenocarcinoma) of the large intestine (colon) * Willingness to participate

Exclusion criteria

* No radical resection (R0) possible * Unwilling to participate or medically unfit to undergo follow-up

Design outcomes

Primary

MeasureTime frame
3-year disease free survival (DFS)2007/10 - 2010/13

Secondary

MeasureTime frame
5-year overall survival (OS)2007/10 - 2012/15

Countries

Norway

Contacts

Primary ContactKarl Sondenaa, MD, PhD
kasoende@online.no+47-91868877
Backup ContactRune Haaverstad, MD, PhD
rune.haaverstad@helse-bergen.no+47-92210911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026